Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-12
2006-12-12
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S146000, C548S215000, C548S250000, C548S408000
Reexamination Certificate
active
07148246
ABSTRACT:
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticalsThe invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives.What is described are compounds of the formula I,in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.
REFERENCES:
patent: 5468762 (1995-11-01), Malamas et al.
patent: 5532256 (1996-07-01), Malamas et al.
patent: 6221633 (2001-04-01), Ertl et al.
patent: 6221897 (2001-04-01), Frick et al.
patent: 6245744 (2001-06-01), Frick et al.
patent: 6277831 (2001-08-01), Frick et al.
patent: 6342512 (2002-01-01), Kirsch et al.
patent: 6710063 (2004-03-01), Choa et al.
patent: 6723740 (2004-04-01), Choa et al.
patent: 0 462 884 (2001-12-01), None
patent: WO 94/18183 (1994-08-01), None
patent: WO 94/18184 (1994-08-01), None
patent: WO 96/38428 (1996-12-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 99/15525 (1999-04-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62871 (1999-12-01), None
patent: WO 99/62872 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 00/63208 (2000-10-01), None
patent: WO 00/64876 (2000-11-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 00/66585 (2000-11-01), None
patent: WO 00/71549 (2000-11-01), None
patent: WO 00/78312 (2000-12-01), None
patent: WO 01/04146 (2001-01-01), None
patent: WO 01/09111 (2001-02-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO 01/40169 (2001-06-01), None
patent: WO 01/40171 (2001-06-01), None
patent: WO 01/72290 (2001-10-01), None
patent: WO 01/81327 (2001-11-01), None
patent: WO 01/83451 (2001-11-01), None
patent: WO 01/85695 (2001-11-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 01/94300 (2001-12-01), None
patent: WO 02/38541 (2002-05-01), None
patent: WO 02/46146 (2002-06-01), None
patent: WO 02/50027 (2002-06-01), None
patent: WO 02/051820 (2002-07-01), None
patent: WO 02/064549 (2002-08-01), None
patent: WO 02/096864 (2002-12-01), None
patent: WO 03/004458 (2003-01-01), None
patent: WO 03/020269 (2003-03-01), None
patent: WO 03/040174 (2003-05-01), None
patent: WO 03/066581 (2003-08-01), None
patent: WO 03/084922 (2003-10-01), None
patent: WO 03/084923 (2003-10-01), None
patent: WO 03/104188 (2003-12-01), None
Malamas et al., “New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties,” Sep. 17, 1999, J. Med. Chem., vol. 43, pp. 995-1010.
Momose et al., “Novel 5-Substituted 1,4-Thiazolidinedione and 2,4-Oxazolidinedione Derivatives as Insulin Sensitizers with Antidiabetic Activities,” Oct. 22, 2001, J. Med. Chem., vol. 45, p. 1518-1534.
Malamas et al., titled “New Azolidinediones as Inhibitors of Protein Tyrosine Phophatase 1B with Antihyperglycemic Properties,” J. Med. Chem., vol. 43 (2000), pp. 995-1010, especially p. 996, Compound 15.
Asakawa, A., et. al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Research; vol. 33(9); 2001; pp. 554-558.
Berger, J., et. al., The Mechanisms of Action of PPARs, Annul. Rev. Med.; vol. 53; 2002; pp. 409-435.
Fruchart, J.C., et. al., PPARs, Metabolic Disease and Atherosclerosis, Pharmacological Research; vol. 44, No. 5; 2001' pp. 345-352.
Kersten, S., et. al., Roles of PPARs in Health and Disease, Nature; vol. 405; May 25, 2000; pp. 421-424.
Kliewer, S.A., et. al., Peroxisome Proliferator-Activated Receptors: From Genes to Physiology, Recent Prog. Horm Res.; vol. 56; 2001; pp. 239-263.
Lee, D.W., et. al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future; vol. 26(9); 2001; pp. 873-881.
Motojima, K., et. al. Peroxisome Proliferator-Activated Receptor (PPAR): Structure, Mechanisms of Activation and Diverse Functions, Cell Structure and Function; vol. 18; 1993; pp. 267-277.
Okada, H., et. al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull.; vol. 42(1); 1994; pp. 57-61.
Pineda Torra, I., et. al., Peroxisome Proliferator-activated Receptors: from Transcriptional Control to Clinical Practice, Curr. Opin. Lipidol; vol. 12; 2001; pp. 245-254.
Pineda Torra, I., et. al., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging, Curr. Opin. Lipidol; vol. 10; 1999; pp. 151-159.
Vidal-Puig, A., et. al., Regulation of PPAR γ Gene Expression by Nutrition and Obesity in Rodents, J. Clin. Invest.; vol. 97, No. 11, 1996; pp. 2553-2561.
Willson, T., M., et. al., The PPARs: From Orphan Receptors to Drug Discovery, Journal of Medicinal Chemistry; vol. 43, No. 4; 2000; pp. 527-550.
Zunft, H.J.F., et. al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Natural Therapy; vol. 18, No. 5; Sep.-Oct., 2001; pp. 230-236.
Falk Eugen
Glombik Heiner
Goerlitzer Jochen
Gretzke Dirk
Keil Stefanie
Chung Susannah L.
Kurys Barbara E.
Saeed Kamal A.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Cycloalkyl derivatives having bioisosteric carboxylic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkyl derivatives having bioisosteric carboxylic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl derivatives having bioisosteric carboxylic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3697771